Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia
Completed
- Conditions
- Undertreatment of Hypercholesterolaemia
- Registration Number
- NCT01027624
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is a multi-centre survey of patients who are currently on lipid lowering pharmacological treatment in South Africa.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
- Subject must be 18 years of age or older of either gender or race.
- Subject must provide informed consent and comply with the survey procedures.
- Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
Exclusion Criteria
- Subjects who are unwilling or unable to provide informed consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III
- Secondary Outcome Measures
Name Time Method Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to the Fourth Joint European Task Force Guidelines/South African Guidelines in primary/secondary prevention patients, patients with metabolic syndrome Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III Proportion of patients on lipid-lowering pharmacological treatment reaching the non HDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III Guidelines
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms contribute to undertreatment of hypercholesterolaemia in South African populations according to NCT01027624?
How does the effectiveness of lipid-lowering therapies in NCT01027624 compare to global standard-of-care protocols for hypercholesterolaemia management?
What biomarkers are associated with treatment response in hypercholesterolaemic patients on lipid-lowering drugs as identified in NCT01027624?
What adverse events are commonly reported in South African patients receiving lipid-lowering pharmacotherapy as per NCT01027624 findings?
What insights does NCT01027624 provide about the therapeutic landscape of hypercholesterolaemia in low-to-middle-income settings compared to statin-based approaches developed by AstraZeneca and other pharmaceutical companies?
Trial Locations
- Locations (1)
Research Site
🇿🇦Johannesburg, South Africa
Research Site🇿🇦Johannesburg, South Africa